Ra Capital Management, L.P. Sells 458,411 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 458,411 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $16.28, for a total value of $7,462,931.08. Following the transaction, the director owned 2,739,208 shares of the company’s stock, valued at $44,594,306.24. This represents a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 20th, Ra Capital Management, L.P. sold 171,963 shares of Vor Biopharma stock. The shares were sold at an average price of $15.77, for a total value of $2,711,856.51.
• On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total value of $8,569,351.50.
• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total value of $858,840.44.
• On Tuesday, April 14th, Ra Capital Management, L.P. sold 153,735 shares of Vor Biopharma stock. The shares were sold at an average price of $15.97, for a total value of $2,455,147.95.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total value of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total value of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total value of $4,739,800.00.

Vor Biopharma Stock Performance

NASDAQ VOR opened at $15.32 on Thursday. The company has a market capitalization of $748.35 million, a P/E ratio of -0.04 and a beta of 1.92. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80. The stock has a 50 day moving average price of $14.84 and a 200-day moving average price of $15.81.

Institutional Trading of Vor Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. purchased a new stake in Vor Biopharma in the fourth quarter worth $36,000. Goldman Sachs Group Inc. increased its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after purchasing an additional 58,247 shares during the period. XTX Topco Ltd purchased a new stake in Vor Biopharma in the second quarter worth $66,000. Chung Wu Investment Group LLC purchased a new stake in Vor Biopharma in the fourth quarter worth $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in Vor Biopharma in the fourth quarter worth $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on VOR shares. Citigroup started coverage on Vor Biopharma in a research report on Friday, January 9th. They issued a “buy” rating and a $50.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Wedbush raised their price target on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Jefferies Financial Group started coverage on Vor Biopharma in a research report on Monday, March 30th. They issued a “buy” rating and a $50.00 price target for the company. Finally, HC Wainwright lowered their price target on Vor Biopharma from $32.00 to $31.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.56.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).